Physician profile
Robert Stahlman
NPI 1679640957
$4,426.66
in general payments reported to CMS, 2019-2025
28 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,469 · 2020: $1,208 · 2021: $635 · 2022: $94.81 · 2023: $137 · 2024: $280 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $680.01 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $573.51 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $548.42 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $362.39 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $283.19 | 2019-2024 | Xarelto |
| Amgen INC. | $238.58 | 2019-2025 | Repatha, Otezla |
| Allergan, INC. | $208.01 | 2019 | |
| Amarin Pharma, INC. | $187.47 | 2019-2021 | |
| Abbvie INC. | $160.70 | 2019-2024 | |
| Glaxosmithkline, LLC. | $146.69 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $125.49 | 2019-2024 | Mounjaro, Zepbound |
| Kowa Pharmaceuticals America, INC. | $119.20 | 2019-2023 | Livalo |
| Medicure Pharma INC. | $116.89 | 2020 | |
| Sanofi-Aventis U.S. LLC | $108.72 | 2019-2021 | |
| Corcept Therapeutics | $106.39 | 2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.73 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $87.19 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $59.72 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $45.57 | 2019-2020 | |
| Dexcom, INC. | $40.08 | 2022 | |
| Eisai INC. | $24.05 | 2021 | |
| Abbott Laboratories | $22.10 | 2024 | Proclaim |
| Scilex Pharmaceuticals INC. | $19.23 | 2021 | |
| Aimmune Therapeutics, INC. | $16.13 | 2025 | Zenpep |
| Cmp Pharma, INC. | $15.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.25 | 2019 | |
| Aytu Biopharma, INC. | $11.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stahlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.